首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Long-term Outcomes After Liver Transplantation Among Human Immunodeficiency Virus-Infected Recipients
【24h】

Long-term Outcomes After Liver Transplantation Among Human Immunodeficiency Virus-Infected Recipients

机译:在人类免疫缺陷病毒感染者中进行肝移植后的长期结果

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background Early outcomes after human immunodeficiency virus (HIV) + liver transplantation (LT) are encouraging, but data are lacking regarding long-term outcomes and comparisons with matched HIV- patients. Methods We examined outcomes among 180 HIV+ LT, and compared outcomes to matched HIV- counterfactuals (Scientific Registry of Transplant Recipients 2002-2011). Iterative expanding radius matching (1:10) on recipient age, race, body mass index, hepatitis C virus (HCV), model for end-stage liver disease score, and acute rejection; and donor age and race, cold ischemia time, and year of transplant. Patient survival and graft survival were estimated using Kaplan-Meier methodology and compared using log-rank and Cox proportional hazards. Subgroup analyses were performed by transplant era (early: 2002-2007 vs modern: 2008-2011) and HCV infection status. Results Compared to matched HIV- controls, HIV+ LT recipients had a 1.68-fold increased risk for death (adjusted hazard ratio [aHR], 1.68, 95% confidence interval [95% CI], 1.28-2.20; P < 0.001), and a 1.70-fold increased risk for graft loss (aHR, 1.70; 95% CI, 1.31-2.20; P < 0.001). These differences persisted independent of HCV infection status. However, in the modern transplant era risk for death (aHR, 1.11; 95% CI, 0.52-2.35; P = 0.79) and graft loss (aHR, 0.89; 95% CI, 0.42-1.88; P = 0.77) were similar between monoinfected and uninfected LT recipients. In contrast, independent of transplant era, coinfected LT recipients had increased risk for death (aHR, 2.24; 95% CI, 1.43-3.53; P < 0.001) and graft loss (aHR, 2.07; 95% CI, 1.33-3.22; P = 0.001) compared to HCV+ alone LT recipients. Conclusions These results suggest that outcomes among monoinfected HIV+ LT recipients have improved over time. However, outcomes among HIV+ LT recipients coinfected with HCV remain concerning and motivate future survival benefit studies.
机译:背景技术人类免疫缺陷病毒(HIV)+肝移植(LT)后的早期结果令人鼓舞,但缺乏长期结果以及与匹配的HIV患者进行比较的数据。方法我们检查了180例HIV + LT患者的结局,并将结果与​​相匹配的HIV反事实进行了比较(移植收件人科学注册处2002-2011)。根据接受者的年龄,种族,体重指数,丙型肝炎病毒(HCV),终末期肝病评分模型和急性排斥反应进行迭代扩展半径匹配(1:10);以及供体的年龄和种族,寒冷的缺血时间和移植年份。使用Kaplan-Meier方法评估患者的生存率和移植物生存率,并使用对数秩和Cox比例风险进行比较。按移植时代(早期:2002-2007年与现代:2008-2011年)和HCV感染状况进行亚组分析。结果与匹配的HIV对照相比,HIV + LT接受者的死亡风险增加了1.68倍(调整后的危险比[aHR],1.68、95%置信区间[95%CI],1.28-2.20; P <0.001),并且移植物丢失风险增加1.70倍(aHR,1.70; 95%CI,1.31-2.20; P <0.001)。这些差异持续存在,与HCV感染状况无关。然而,在现代移植时代,死亡风险(aHR,1.11; 95%CI,0.52-2.35; P = 0.79)和移植物丢失(aHR,0.89; 95%CI,0.42-1.88; P = 0.77)之间相似单一感染和未感染的LT受体。相比之下,与移植时代无关,合并感染的LT受体的死亡风险(aHR为2.24; 95%CI为1.43-3.53; P <0.001)和移植物丢失(aHR为2.07; 95%CI为1.33-3.22; P = 0.001),而仅是HCV + LT接受者。结论这些结果表明,单次感染HIV + LT接受者的结局随着时间的推移而有所改善。然而,在合并了HCV的HIV + LT接受者中,结局仍然令人担忧,并激发了未来的生存获益研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号